Apollomics (APLM) Stock Price, News & Analysis

Company Overview

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Key Stats

• Today's Range: $6.15 to $6.66
• 50-Day Range: $5.32 to $7.26
• 52-Week Range: $4.47 to $35.98
• Volume: 32,508 shs
• Average Volume: 61,420 shs
• Market Capitalization: $6.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Apollomics Stock Analysis - MarketRank™

Apollomics scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Apollomics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Apollomics has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.56% of the float of Apollomics has been sold short.

Short Interest Ratio / Days to Cover

Apollomics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apollomics has recently decreased by 40.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apollomics does not currently pay a dividend.

Dividend Growth

Apollomics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.56% of the float of Apollomics has been sold short.

Short Interest Ratio / Days to Cover

Apollomics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apollomics has recently decreased by 40.26%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Apollomics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Apollomics this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for APLM on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Apollomics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 19.13% of the stock of Apollomics is held by institutions.

APLM Stock Analysis - Frequently Asked Questions

How have APLM shares performed this year?

Apollomics' stock was trading at $9.75 at the beginning of 2025. Since then, APLM shares have decreased by 36.1% and is now trading at $6.23.

When did Apollomics' stock split?

Apollomics's stock reverse split on the morning of Monday, November 25th 2024.The 1-100 reverse split was announced on Thursday, November 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Apollomics?

Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Apollomics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Apollomics investors own include NVIDIA (NVDA), Cara Therapeutics (CARA), Akebia Therapeutics (AKBA), Avino Silver & Gold Mines (ASM), Canoo (GOEV), MSP Recovery (LIFW) and Tempest Therapeutics (TPST).

Company Calendar

• Today: 7/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:APLM
• CIK: 1944885
• Web: www.apollomicsinc.com
• Phone: 886-2-7713-7952
• Fax: 650-288-1674
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.39
• Quick Ratio: 1.39

Sales & Book Value

• Annual Sales: $1.49 million
• Price / Sales: 4.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.48 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 1,100,000
• Free Float: N/A
• Market Cap: $6.85 million
• Optionable: Not Optionable
• Beta: 0.93